whatshot

ALRN   $3.18  8.90% Market Open

Aileron Therapeutics Inc
show_chart Advanced Chart of ALRN
Last Events:

2023-08-09 Trend pattern changed from канал to расходящийся клин с наклоном вверх.

2023-08-09 Trend Power changed from slow to medium strength.

2023-08-06 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-05 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-05 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-05 Trend Power changed from medium strength to slow.

2023-08-04 Trend Power changed from strong to medium strength.

2023-08-02 Signal in MACD changed from bearish reversal to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: down-crossing the middle level.

Current temperature: 7.52
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 2
Target Price Mean 13.0000
Mean unverified/preliminary 13.0000 / 13.0000
Target Price Low / High 7.0000 / 19.0000
Median / STD DEV 13.0000 / 8.49
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Sell Sell
rsi Sell None Sell
macd None None None
stoch None None None
ma20 ActivelyBuy Sell None
ma50 None None None
ma100 Sell Sell None
Candlestick PatternSept. 10, 2024 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US00887A2042
ceo Dr. James Brian Windsor Ph.D.
Website https://www.aileronrx.com
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.